AlloVir (ALVR) Competitors $0.40 -0.05 (-10.22%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALVR vs. CMPX, MGNX, ADCT, CADL, INZY, CYBN, PRQR, SLN, ALEC, and LYELShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Compass Therapeutics (CMPX), MacroGenics (MGNX), ADC Therapeutics (ADCT), Candel Therapeutics (CADL), Inozyme Pharma (INZY), Cybin (CYBN), ProQR Therapeutics (PRQR), Silence Therapeutics (SLN), Alector (ALEC), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Compass Therapeutics MacroGenics ADC Therapeutics Candel Therapeutics Inozyme Pharma Cybin ProQR Therapeutics Silence Therapeutics Alector Lyell Immunopharma AlloVir (NASDAQ:ALVR) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends. Do analysts rate ALVR or CMPX? Compass Therapeutics has a consensus target price of $6.75, suggesting a potential upside of 389.13%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60Compass Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has stronger earnings & valuation, ALVR or CMPX? Compass Therapeutics has higher revenue and earnings than AlloVir. Compass Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlloVirN/AN/A-$190.42M-$0.88-0.46Compass Therapeutics$850K223.38-$42.49M-$0.37-3.73 Which has more volatility & risk, ALVR or CMPX? AlloVir has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Does the media refer more to ALVR or CMPX? In the previous week, AlloVir and AlloVir both had 1 articles in the media. Compass Therapeutics' average media sentiment score of 1.92 beat AlloVir's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AlloVir 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals and insiders believe in ALVR or CMPX? 66.1% of AlloVir shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Comparatively, 28.5% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in ALVR or CMPX? Compass Therapeutics received 3 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 73.17% of users gave Compass Therapeutics an outperform vote while only 57.45% of users gave AlloVir an outperform vote. CompanyUnderperformOutperformAlloVirOutperform Votes2757.45% Underperform Votes2042.55% Compass TherapeuticsOutperform Votes3073.17% Underperform Votes1126.83% Is ALVR or CMPX more profitable? Compass Therapeutics' return on equity of -32.37% beat AlloVir's return on equity.Company Net Margins Return on Equity Return on Assets AlloVirN/A -71.03% -61.27% Compass Therapeutics N/A -32.37%-30.67% SummaryCompass Therapeutics beats AlloVir on 13 of the 15 factors compared between the two stocks. Ad Weiss RatingsNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.69M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-0.4646.7391.3417.19Price / SalesN/A411.851,116.59116.80Price / CashN/A182.1042.6437.86Price / Book0.323.894.794.78Net Income-$190.42M-$42.21M$120.07M$225.60M7 Day Performance-10.22%-2.14%-1.89%-1.24%1 Month Performance-30.04%4.21%11.45%3.36%1 Year Performance-82.66%18.40%30.61%16.58% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVir0.7122 of 5 stars$0.40-10.2%N/A-81.8%$46.69MN/A-0.46110News CoverageCMPXCompass Therapeutics2.6637 of 5 stars$1.460.0%$6.75+362.4%-13.2%$200.85M$850,000.00-4.0720MGNXMacroGenics3.5293 of 5 stars$3.20flat$7.63+138.3%-67.7%$200.84M$139.77M-2.03430ADCTADC Therapeutics3.0991 of 5 stars$2.06+9.0%$8.00+288.3%+51.9%$199.18M$70.72M-0.86310Gap UpCADLCandel Therapeutics2.7535 of 5 stars$6.13-9.2%$11.00+79.4%+681.3%$199.08M$120,000.00-3.6060Analyst ForecastInsider TradeAnalyst RevisionGap DownHigh Trading VolumeINZYInozyme Pharma1.8484 of 5 stars$3.08+1.7%$17.00+451.9%-23.7%$197.86MN/A-2.0850CYBNCybin1.5544 of 5 stars$9.87+0.9%$138.00+1,298.2%N/A$197.30MN/A-1.4950PRQRProQR Therapeutics2.2288 of 5 stars$2.41-14.8%$7.60+215.4%+34.2%$196.85M$7.05M-8.13180Gap DownHigh Trading VolumeSLNSilence Therapeutics3.4366 of 5 stars$6.54+1.4%$57.20+774.6%-59.0%$195.74M$31.55M-4.11100ALECAlector4.2479 of 5 stars$1.99+1.0%$4.00+101.0%-76.4%$194.89M$61.51M-1.16270Analyst DowngradeLYELLyell Immunopharma2.2277 of 5 stars$0.66-1.6%$1.00+50.8%-69.1%$193.76M$63,000.00-0.85270Gap Down Related Companies and Tools Related Companies CMPX Alternatives MGNX Alternatives ADCT Alternatives CADL Alternatives INZY Alternatives CYBN Alternatives PRQR Alternatives SLN Alternatives ALEC Alternatives LYEL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALVR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
